Itrostred 200 Capsule contains Itraconazole 200 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various systemic and superficial fungal infections caused by susceptible fungi, including aspergillosis, blastomycosis, histoplasmosis, and onychomycosis. Itraconazole exerts its antifungal effect by inhibiting the fungal cytochrome P450 enzyme 14α-demethylase, which is essential for the synthesis of ergosterol, a critical component of the fungal cell membrane. Disruption of ergosterol synthesis results in increased membrane permeability and ultimately fungal cell death. Itrostred 200 Capsule is administered orally and demonstrates good bioavailability, with absorption enhanced when taken with food. The drug is extensively metabolized in the liver via the cytochrome P450 system, necessitating caution in patients with hepatic impairment and potential drug interactions. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Due to its potent inhibition of CYP3A4, co-administration with certain medications may lead to significant interactions. Itrostred 200 Capsule should be used under medical supervision, with appropriate monitoring to ensure efficacy and safety during antifungal therapy.